FDA warning on Vytorin

The FDA has issued a warning on the use of vytorin (simvastatin/ezetimibe) given the results of a recent randomized trial which showed vytorin was associated with a higher risk of cancer/cancer-related deaths compared to placebo. The FDA is not advising prescribers to stop using the medication at all, but to consider the benefits and risks compared to other lipid-lowering medications (FDA site)

Danielle Scheurer

Dr. Scheurer is a clinical hospitalist and the Medical Director of Quality and Safety at the Medical University of South Carolina in Charleston, South Carolina, and is Assistant Professor of Medicine. She is a graduate of the University of Tennessee College of Medicine, completed her residency at Duke University, and completed her Masters in Clinical Research at the Medical University of South Carolina. She also serves as the Web Editor and Physician Advisor for the Society of Hospital Medicine.

Leave a Comment